179 related articles for article (PubMed ID: 3460995)
1. Antigen detection by the monoclonal antibodies CA 19-9 and CA 125 in normal and tumor tissue and patients' sera.
Dietel M; Arps H; Klapdor R; Müller-Hagen S; Sieck M; Hoffmann L
J Cancer Res Clin Oncol; 1986; 111(3):257-65. PubMed ID: 3460995
[TBL] [Abstract][Full Text] [Related]
2. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
Suzuki H; Teshima K; Noda K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2719-23. PubMed ID: 6594978
[TBL] [Abstract][Full Text] [Related]
3. Radioimmunoassay of the CA 12 5 antigen in ovarian carcinomas: advantages compared with CA 19-9 and CEA.
Ricolleau G; Chatal JF; Fumoleau P; Kremer M; Douillard JY; Curtet C
Tumour Biol; 1984; 5(3-4):151-9. PubMed ID: 6594738
[TBL] [Abstract][Full Text] [Related]
4. Expression of monoclonal antibody-defined tumor markers in four carcinomas.
Wu JT
Ann Clin Lab Sci; 1989; 19(1):17-26. PubMed ID: 2916833
[TBL] [Abstract][Full Text] [Related]
5. [CA 15-3 is present as a novel tumor marker in the sera of patients with breast cancer and other malignancies].
Gang Y; Adachi I; Ohkura H; Yamamoto H; Mizuguchi Y; Abe K
Gan To Kagaku Ryoho; 1985 Dec; 12(12):2379-86. PubMed ID: 3865634
[TBL] [Abstract][Full Text] [Related]
6. Serum levels and biochemical characteristics of cancer-associated antigen CA-549, a circulating breast cancer marker.
Bray KR; Koda JE; Gaur PK
Cancer Res; 1987 Nov; 47(22):5853-60. PubMed ID: 2444335
[TBL] [Abstract][Full Text] [Related]
7. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients.
Takasaki H; Uchida E; Tempero MA; Burnett DA; Metzgar RS; Pour PM
Cancer Res; 1988 Mar; 48(6):1435-8. PubMed ID: 3162196
[TBL] [Abstract][Full Text] [Related]
8. [Monoclonal antibodies in the diagnosis and follow-up of ovarian cancer. CA 125 as a tumor marker. A cooperative study of the Gynecologic Tumor Marker Group (GTMG)].
Kaesemann H; Caffier H; Hoffmann FJ; Crombach G; Würz H; Kreienberg R; Möbus V; Schmidt-Rhode P; Sturm G
Klin Wochenschr; 1986 Sep; 64(17):781-5. PubMed ID: 3463828
[TBL] [Abstract][Full Text] [Related]
9. Improved specificity of the CA 125 enzyme immunoassay for ovarian carcinomas by use of the ratio of CA 125 to carcinoembryonic antigen.
Wu JT; Miya T; Knight JA; Knight DP
Clin Chem; 1988 Sep; 34(9):1853-7. PubMed ID: 2458203
[TBL] [Abstract][Full Text] [Related]
10. Tissue expression of the tumor marker CA 50 in benign and malignant pancreatic lesions. A comparison with CA 19-9.
Haglund C; Lindgren J; Roberts PJ; Nordling S
Int J Cancer; 1986 Dec; 38(6):841-6. PubMed ID: 3466871
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease.
Blind PJ; Dahlgren ST
Acta Chir Scand; 1987 Jan; 153(1):45-9. PubMed ID: 3472420
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of new three tumor markers for pancreatic carcinoma: CA19/9, CA 125 and DuPan 2].
Ohkura H; Sakawaki T
Gan No Rinsho; 1985 May; 31(6 Suppl):583-8. PubMed ID: 3861882
[TBL] [Abstract][Full Text] [Related]
13. A study of the Ca antigen in epithelial tumours of the ovary.
Ferguson AM; Fox H
J Clin Pathol; 1984 Jan; 37(1):6-9. PubMed ID: 6368598
[TBL] [Abstract][Full Text] [Related]
14. Measurement of a pancreatic cancer-associated antigen (DU-PAN-2) detected by a monoclonal antibody in sera of patients with digestive cancers.
Sawabu N; Toya D; Takemori Y; Hattori N; Fukui M
Int J Cancer; 1986 May; 37(5):693-6. PubMed ID: 3457770
[TBL] [Abstract][Full Text] [Related]
15. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
[TBL] [Abstract][Full Text] [Related]
16. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.
Tempero MA; Uchida E; Takasaki H; Burnett DA; Steplewski Z; Pour PM
Cancer Res; 1987 Oct; 47(20):5501-3. PubMed ID: 3308077
[TBL] [Abstract][Full Text] [Related]
17. Tumor antigen NB/70K and CA 125 levels in the blood of preoperative ovarian cancer patients and controls: a preliminary report of the use of the NB12123 and CA 125 radioimmunoassays alone and in combination.
Knauf S; Bast RC
Int J Biol Markers; 1988; 3(2):75-81. PubMed ID: 3243980
[TBL] [Abstract][Full Text] [Related]
18. Clinical usefulness of three monoclonal antibody-defined tumor markers: CA 19-9, CA 50, and CA 125.
Szymendera JJ
Tumour Biol; 1986; 7(5-6):333-42. PubMed ID: 2437641
[TBL] [Abstract][Full Text] [Related]
19. Immunoperoxidase localization of a high-molecular-weight mucin recognized by monoclonal antibody 1D3.
Gangopadhyay A; Bhattacharya M; Chatterjee SK; Barlow JJ; Tsukada Y
Cancer Res; 1985 Apr; 45(4):1744-52. PubMed ID: 3884144
[TBL] [Abstract][Full Text] [Related]
20. Serum CA 50 as a tumor marker in pancreatic cancer: a comparison with CA 19-9.
Haglund C; Kuusela P; Jalanko H; Roberts PJ
Int J Cancer; 1987 Apr; 39(4):477-81. PubMed ID: 3470260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
